Description

Busulfan (CAS 55-98-1) is a bifunctional alkylating agent with the molecular formula C₆H₁₄O₆S₂ and the IUPAC name 4-methylsulfonyloxybutyl methanesulfonate. This white crystalline solid is a highly potent chemotherapeutic agent primarily used in conditioning regimens prior to hematopoietic stem cell transplantation. Busulfan exhibits exceptional stability under standard storage conditions and is soluble in organic solvents such as acetone and ethanol, though poorly soluble in water. As a DNA alkylating agent, it crosslinks DNA strands, inhibiting replication and transcription processes. Our high-purity Busulfan is rigorously tested via HPLC (>98% purity) and meets stringent pharmacopeial standards for research and clinical applications. Available in gram to kilogram quantities with comprehensive analytical documentation including NMR, MS, and COA.

Properties

• CAS Number: 55-98-1
• Complexity: 293
• IUPAC Name: 4-methylsulfonyloxybutyl methanesulfonate
• InChI: InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
• InChI Key: COVZYZSDYWQREU-UHFFFAOYSA-N
• Exact Mass: 246.02318051
• Molecular Formula: C6H14O6S2
• Molecular Weight: 246.3
• SMILES: CS(=O)(=O)OCCCCOS(=O)(=O)C
• Topological: 104
• Monoisotopic Mass: 246.02318051
• Physical Description: Myleran appears as white crystals or powder.
• Color/Form: White needles
• Melting Point: 237 to 244 °F
• Solubility: Decomposes
• Stability/Shelf Life: … Solutions of busulfan diluted in 0.9% sodium chloride injection also have been shown to be stable when refrigerated at 2-8 °C for up to 12 hours, during which time the infusion must be completed.
• Synonyms: busulfan, 55-98-1, Myleran, Busulphan, Leucosulfan, Myeloleukon, Mielucin, Misulban, Sulfabutin, 1,4-BUTANEDIOL DIMETHANESULFONATE, 1,4-Dimesyloxybutane, Myeleukon, 1,4-Butanediol, dimethanesulfonate, Busulfano, Busulfanum, butane-1,4-diyl dimethanesulfonate, Myelosanum, 1,4-Dimethanesulfonoxybutane, Busilvex, 1,4-Bis(methanesulfonoxy)butane, 1,4-Butanediol dimethylsulfonate, Mitosan, GT 41, CB 2041, Tetramethylene bis(methanesulfonate), Methanesulfonic acid, tetramethylene ester, GT 2041, 1,4-Butanediyl dimethanesulfonate, 1,4-Butanediol, dimethanesulphonate, Bisulfex, NSC750, CHEBI:28901, Busulfex IV, Tetramethylene bis[methanesulfonate], G1LN9045DK, DTXSID3020910, 1,4-Bis[methanesulfonoxy]butane, DTXCID10910, BUSULFAN FRESENIUS KABI, BUSULFAN (IARC), BUSULFAN [IARC], TETRAMETHYLENE DI(METHANESULFONATE), BUSULFAN (MART.), BUSULFAN [MART.], BUSULFAN (EP IMPURITY), BUSULFAN [EP IMPURITY], BUSULFAN (EP MONOGRAPH), BUSULFAN [EP MONOGRAPH], BUSULFAN (USP MONOGRAPH), BUSULFAN [USP MONOGRAPH], Bussulfam, Joacamine, Misulfan, (1,4-Bis(methanesulfonyloxy)butane), 1,4-Dimethanesulphonoxybutane, 1,4-Dimethylsulphonoxy-butane, Tetramethylenedimethanesulfonate, 1,4-di(methylsulfonyloxy)butane, 1,4-Bis(methanesulphonoxy)butane, 1,4-di(methanesulfonyloxy)butane, L01AB01, 1, 4-Bis(methanesulfonoxy)butane, 1,4-BUTANEDIOL DIMESYLATE, GT-41, Tetramethylene bis(methanesulphonate), CB-2041, methanesulfonic acid tetramethylene ester, 1,4-Bitanediol Dimethanesulfonate Esters, WR-19508, Methanesulphonic acid, tetramethylene ester, 200-250-2, BUS, Sulphabutin, Busulfex, Myelosan, Citosulfan, Mitostan, Mylecytan, Mablin, Mielevcin, Milecitan, Mielosan, Mileran, Buzulfan, Tetramethylene dimethane sulfonate, Busulphane, 1,4-Dimethylsulfonyloxybutane, NCI-C01592, 1,4-Dimethanesulfonyloxybutane, 1,4-Dimethylsulfonoxybutane, 1,4-Bis(methanesulfonyloxy)butane, 4-methylsulfonyloxybutyl methanesulfonate, NSC-750, 1,4-Butanediol dimethanesulphonate, AN 33501, 1,4-Dimethanesulphonyloxybutane, NSC 750, Tetramethylenester kyseliny methansulfonove, C.B. 2041, X 149, MFCD00007562, 2041 C. B., G.T. 41, 4-(methanesulfonyloxy)butyl methanesulfonate, NCGC00090905-06, Busulfanum [INN-Latin], Busulfano [INN-Spanish], Methanesulfonic, CAS-55-98-1, CCRIS 418, Busulfan; Butane-1,4-diyl di(methanesulfonate), SR-01000765405, EINECS 200-250-2, BRN 1791786, UNII-G1LN9045DK, AI3-25012, Busulfan/Myleran, Busulfan [USP:INN:BAN:JAN], HSDB 7605, Tetramethylenester kyseliny methansulfonove [Czech], Prestwick_989, Tetramethylene {bis[methanesulfonate]}, Spectrum_000092, BUSULFAN [HSDB], BUSULFAN [INN], BUSULFAN [JAN], 2041 C.B., BUSULFAN [MI], BUSULFAN [VANDF], Spectrum2_000067, Spectrum3_000320, Spectrum4_000259, Spectrum5_000928, BUSULFAN [WHO-DD], BUSULFAN [WHO-IP], CHEMBL820, NCIMech_000192, SCHEMBL4373, BUSULFAN [EMA EPAR], MYELOSANUM [WHO-IP], WLN: WS1&O4OSW1, BSPBio_001920, KBioGR_000698, KBioSS_000512, MLS001076666, Busulfan (Myleran, Busulfex), DivK1c_000847, SPECTRUM1500152, Busulfan (JP18/USP/INN), SPBio_000253, BUSULFAN [ORANGE BOOK], GTPL7136, COVZYZSDYWQREU-UHFFFAOYSA-, HMS502K09, KBio1_000847, KBio2_000512, KBio2_003080, KBio2_005648, KBio3_001420, butane-1,4-diyldimethanesulfonate, BUSULFANUM [WHO-IP LATIN], NINDS_000847, HMS1920I07, HMS2091O09, HMS2233H04, HMS3259G15, HMS3370E11, HMS3655A21, HMS3712A20, HMS5079P12, Pharmakon1600-01500152, HY-B0245, MSK10327, Tox21_111038, Tox21_201848, Tox21_300318, 1, {4-Bis[methanesulfonoxy]butane}, 2041CB, AC-198, BDBM50237623, CCG-35458, NSC755916, s1692, AKOS003614975, Tox21_111038_1, DB01008, FB19365, KS-5212, NC00498, NSC-755916, IDI1_000847, NCGC00090905-01, NCGC00090905-02, NCGC00090905-03, NCGC00090905-04, NCGC00090905-05, NCGC00090905-07, NCGC00090905-08, NCGC00090905-09, NCGC00090905-10, NCGC00090905-11, NCGC00090905-12, NCGC00254038-01, NCGC00259397-01, 4-(methylsulfonyloxy)butyl methylsulfonate, NCI60_041640, SMR000058613, SY029743, SBI-0051300.P003, B1022, NS00010142, ST45022142, SW198555-3, C06862, D00248, D88731, EN300-118686, 4-[(Methylsulfonyl)oxy]butyl methanesulfonate #, AB00051929-10, AB00051929-11, AB00051929_12, AB00051929_14, Busulfan, analytical standard, for drug analysis, Q348922, SR-01000765405-2, SR-01000765405-3, SR-01000765405-7, BRD-K23204545-001-15-6, BRD-K23204545-001-16-4, BRD-K23204545-001-18-0, Busulfan, European Pharmacopoeia (EP) Reference Standard, Z276508890, 1,4-Butanediol-dimethanesulfonate esters;Busulphan;CB-2041, InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

Application

Busulfan is widely utilized as a myeloablative conditioning agent prior to bone marrow or stem cell transplantation in hematologic malignancies. It demonstrates particular efficacy in chronic myeloid leukemia (CML) treatment protocols. Recent research explores its potential in gene therapy conditioning regimens due to its potent immunosuppressive properties. The compound is also investigated for combination therapies with novel targeted agents in refractory hematologic disorders.

Safety and Hazards

GHS Hazard Statements

• H301: Toxic if swallowed [Danger Acute toxicity, oral]
• H340: May cause genetic defects [Danger Germ cell mutagenicity]
• H350: May cause cancer [Danger Carcinogenicity]
• H360: May damage fertility or the unborn child [Danger Reproductive toxicity]
• H371: May cause damage to organs [Warning Specific target organ toxicity, single exposure]
• H373: May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

Precautionary Statements

• P203, P260, P264, P270, P280, P301+P316, P308+P316, P318, P319, P321, P330, P405, and P501

Hazard Classes and Categories

• Acute Tox. 2 (17.6%)
• Acute Tox. 3 (82.4%)
• Acute Tox. 2 (78.4%)
• Skin Irrit. 2 (17.6%)
• Eye Irrit. 2 (17.6%)
• Acute Tox. 2 (80.4%)
• STOT SE 3 (17.6%)
• Muta. 1B (17.6%)
• Carc. 1A (100%)
• Repr. 1A (13.7%)
• STOT RE 2 (13.7%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.